- Home
- BARK vs AVIR Comparison
BARK vs AVIR Comparison
Compare BARK & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BARK
- AVIR
- Stock Information
- Founded
- BARK 2011
- AVIR 2012
- Country
- BARK United States
- AVIR United States
- Employees
- BARK N/A
- AVIR N/A
- Industry
- BARK Department/Specialty Retail Stores
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- BARK Consumer Discretionary
- AVIR Health Care
- Exchange
- BARK Nasdaq
- AVIR Nasdaq
- Market Cap
- BARK 308.9M
- AVIR 247.5M
- IPO Year
- BARK N/A
- AVIR 2020
- Fundamental
- Price
- BARK $2.32
- AVIR $2.94
- Analyst Decision
- BARK Buy
- AVIR Hold
- Analyst Count
- BARK 2
- AVIR 1
- Target Price
- BARK $2.20
- AVIR $6.88
- AVG Volume (30 Days)
- BARK 1.3M
- AVIR 215.7K
- Earning Date
- BARK 11-07-2024
- AVIR 11-07-2024
- Dividend Yield
- BARK N/A
- AVIR N/A
- EPS Growth
- BARK N/A
- AVIR N/A
- EPS
- BARK N/A
- AVIR N/A
- Revenue
- BARK $488,881,000.00
- AVIR N/A
- Revenue This Year
- BARK $3.23
- AVIR N/A
- Revenue Next Year
- BARK $10.01
- AVIR N/A
- P/E Ratio
- BARK N/A
- AVIR N/A
- Revenue Growth
- BARK N/A
- AVIR N/A
- 52 Week Low
- BARK $0.71
- AVIR $2.86
- 52 Week High
- BARK $2.31
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- BARK 77.27
- AVIR 34.81
- Support Level
- BARK $2.09
- AVIR $2.86
- Resistance Level
- BARK $2.24
- AVIR $3.54
- Average True Range (ATR)
- BARK 0.14
- AVIR 0.14
- MACD
- BARK 0.05
- AVIR -0.03
- Stochastic Oscillator
- BARK 99.42
- AVIR 11.76
About BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).